Mr. Coats has been our president and chief executive officer and a director since July 2014. Mr. Coats served in a series of leadership positions at Eisai Inc. and Eisai Corporation of North America, U.S. subsidiaries of Tokyo-based Eisai Co., Ltd., from 1996 through June 2014, including as chief executive officer of Eisai Inc. from 2010 to June 2014. In this role, Mr. Coats helped establish Eisai as a leading innovator of medicines for oncology and specialty therapeutic areas, and he oversaw the expansion of Eisai’s business across the Americas and improved profitability for all of its U.S.-based operating units. In addition, Mr. Coats served as president and chief operating officer of Eisai Inc. from 2004 to 2010 and led the diversification of its business through over $5 billion in strategic acquisitions and licensing and partnership transactions. Mr. Coats also previously held a variety of sales and management positions at Janssen Pharmaceuticals, Inc., a division of Johnson & Johnson, from 1988 to 1996. Mr. Coats is also a member of the board of directors for Blueprint Medicines. Mr. Coats holds a B.S. from Oakland University.
Dr. Lapuerta is our executive vice president and chief medical officer and previously served in a number of other roles since joining Lexicon in 2011, including executive vice president, safety, pharmacovigilance and medical affairs and executive vice president, clinical development. Prior to joining Lexicon, Dr. Lapuerta was a vice president at Bristol-Myers Squibb Company with responsibility for global development of an Alzheimer’s disease drug candidate. He also served as senior vice president, clinical strategy and chief medical officer for Cogentus Pharmaceuticals, Inc. He holds a B.A. in biology from Harvard College and an M.D. from Harvard Medical School.
Dr. Main is our executive vice president, CMC and supply operations and has been with Lexicon for more than 15 years, having also served as executive vice president of pharmaceutical research and senior vice president, Lexicon Pharmaceuticals. Previously, he was president and chief executive officer of Coelacanth Corporation, a leader in using proprietary chemistry technologies to rapidly discover new chemical entities for drug development, until it was acquired by Lexicon in 2001. Dr. Main was formerly senior vice president, U.S. Research, for Novartis Pharmaceuticals Corporation, where he worked for 20 years. Dr. Main holds a B.S. from the University of Aberdeen, Scotland and a Ph.D. in organic chemistry from the University of Liverpool, England. He has also completed postdoctoral studies at the Woodward Research Institute.
Alexander A. Santini has been our chief commercial officer since November 2016 and previously served as vice president, market access and head of market access and channel management since joining our company in April 2015. Mr. Santini served in a series of leadership positions at Bayer Healthcare Pharmaceuticals from 2006 to October 2014, most recently as vice president of market access and executive member, where he had executive responsibility for market access, pricing, trade and channel management and payer account management. Prior to 2006, Mr. Santini held executive leadership roles of increasing responsibility at Berlex Laboratories, where he worked for 22 years before joining Bayer. Mr. Santini served as a non-commissioned officer in the United States Air Force, where he completed the Radiologic Technology Program at the United States Air Force School of Health Care Science and an AAS in business marketing from Westchester Community College.
Dr. Tyle has been our executive vice president of research and development since May 2016. Dr. Tyle was previously a member of the executive management team at Osmotica Pharmaceutical Corp., serving as president and chief executive officer from January 2013 through April 2016 and as executive vice president and chief scientific officer from August 2012 to December 2012. Prior to his service at Osmotica, Dr. Tyle held a series of leadership positions within the pharmaceutical industry, including executive vice president and chief science officer for the United States Pharmacopeia, senior vice president and global head of research and development and business development and licensing at Novartis OTC, corporate senior vice president of global research and development and chief scientific officer at Bausch & Lomb Incorporated and vice president and global head of pharmaceutical sciences at Pharmacia Corporation. Dr. Tyle received his B.Pharm. from the Indian Institute of Technology, Banaras Hindu University and his Ph.D. in pharmaceutics and pharmaceutical chemistry from the Ohio State University.
Mr. Wade is our executive vice president, corporate and administrative affairs and chief financial officer. Mr. Wade has been with Lexicon since 1999 and has served in a number of roles, including executive vice president, corporate development and chief financial officer and executive vice president and general counsel. Prior to joining Lexicon, he was a corporate securities and finance attorney with the law firm of Andrews & Kurth L.L.P., most recently as a partner, where he represented companies in the biotechnology, information technology and energy industries. Mr. Wade is a member of the board of directors of the Texas Healthcare and Bioscience Institute. He received his B.A. and J.D. from the University of Texas.
Mr. Tessmer is our vice president, finance and accounting and has held a number of senior finance roles within Lexicon since joining the company in 2001. Previously, Mr. Tessmer was assistant controller for Mariner Health Network, Inc., and also served in a variety of financial and accounting management positions for HWC Distribution Corp. and American General Corporation. Mr. Tessmer is a certified public accountant and received a B.B.A. from the University of Wisconsin–Milwaukee and an M.B.A. from the University of Houston.